Literature DB >> 8512043

Contraceptive choices in women with coagulation disorders.

P C Comp1, H A Zacur.   

Abstract

When compared with older reports on the thromboembolic effects of high-dose oral contraceptives, new studies with low-dose oral contraceptives have a significantly reduced risk of thromboembolism. In the absence of risk factors such as smoking or inherited disorders predisposing to thrombosis, the modern low-dose oral contraceptive (< 50 micrograms of estrogen) is a safe and effective choice for contraception in women without symptoms who have family histories of sporadic thromboembolism. An intrauterine device or some form of barrier method is recommended for women who have a personal history of venous thrombus disease. The low-dose oral contraceptive may be a good choice in women taking oral anticoagulants because of the risk of teratogenic effects of anticoagulants and the risks of intraperitoneal bleeding associated with ovulation. In addition, oral contraceptives help diminish the excessive menstrual bleeding often seen in these women.

Entities:  

Keywords:  Antibodies; Biology; Blood Coagulation Effects--women; Contraception; Contraceptive Methods--contraindications; Contraceptive Methods--side effects; Diseases; Drugs; Embolism; Endocrine System; Estrogens; Family Planning; Heart Diseases--women; Hematological Effects; Hemic System; Hormones; Immunity; Immunologic Factors; Literature Review; Oral Contraceptives, Low-dose; Oral Contraceptives--contraindications; Oral Contraceptives--side effects; Physiology; Progestational Hormones; Progesterone; Pulmonary Embolism; Recommendations; Surgery; Thromboembolism--women; Thrombosis--etiology; Treatment; Vascular Diseases

Mesh:

Substances:

Year:  1993        PMID: 8512043     DOI: 10.1016/s0002-9378(12)90940-0

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  1 in total

1.  Family planning requirements in the adult congenital heart disease clinic.

Authors:  H Leonard; J J O'Sullivan; S Hunter
Journal:  Heart       Date:  1996-07       Impact factor: 5.994

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.